AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01413594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT
Description: 90 hours of bimanual training over 3 weeks in a day camp environment
Study NCT04463524 — intervention group
Intervention type: DEVICE
Intervention: Personal ECG digital sensor
Description: Patients in test group will receive personal ECG sensor and in control gropu will not.
Study NCT04083196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Description: Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle
Study NCT01137903 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conservative surgery
Description: Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy
Study NCT01137903 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin
Description: 500 mg/ 12 hours during 90 days
Study NCT01137903 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: 875/125 mg/12 hours during 90 days
Study NCT01137903 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sulfamethoxazole trimethoprim
Description: Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.
Study NCT00603980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 2 mg
Description: Oral alprazolam 2 mg + Inhaled placebo
Study NCT02363439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
Description: IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
Study NCT00792584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etravirine
Description: Patient receives etravirine/ placebo or efavirenz / placebo
Study NCT00792584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: patient receives efavirenz / placebo or etravirine / placebo
Study NCT03791294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions
Description: TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
Study NCT04122781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel K-wire fixation devices
Description: The patients received surgery using novel K-wire fixation devices
Study NCT04122781 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel K-wire fixation devices
Description: The patients received surgery using novel K-wire fixation devices
Study NCT00688298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefyx PPS™ System
Description: A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
Study NCT00688298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advantage ™ System
Description: The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
Study NCT03965624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ninlaro
Description: Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
Study NCT01719562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
Study NCT01719562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Tailored aerobic exercise program onsite and at home.
Study NCT01719562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Living
Description: Healthy living presentations at a centralized meeting place and over the phone.
Study NCT01719562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing (CPET)
Description: Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.
Study NCT01719562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: A self-administered 13-item scale to assess fatigue in participants
Study NCT00263887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha1-Proteinase Inhibitor (Human)
Description: Weekly infusion of 60 mg/kg body weight for 2 years
Study NCT00263887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin (Human) 20%, United States Pharmacopeia (USP)
Description: Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
Study NCT01503333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Receiving individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
Study NCT04635332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food literacy and physical activity promotion interactive group sessions + Developed health promotion intervention materials (booklet)
Description: Information, skills training, goal setting and feedback interactive group sessions to improve food literacy aimed at increasing consumption of fruits and vegetables~Information, skills training, goal setting and feedback interactive group sessions to increase engagement in moderate physical activity~Information and skills training to increase ability to evaluate nutrition information~In general, focus will be on increasing knowledge, skills and self-efficacy to develop a lifelong healthy and gastronomic relationship with food and physical activity.
Study NCT04635332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developed health promotion intervention materials (booklet).
Description: In the control arm, participants will only be given the developed intervention materials (designed in form of the usual awareness programs). No group sessions will be conducted
Study NCT00504478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: omega-3 supplement will be given in addition to high complex carbohydrate diet.
Study NCT00504478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high complex carbohydrate diet
Study NCT02394639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video-EEG monitoring
Study NCT02394639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-EEG monitoring
Study NCT03081728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml
Description: bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
Study NCT03081728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV diclofenac and IV paracetamol
Description: iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
Study NCT03270592 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Service dog
Description: Use of a individualized certified service dog
Study NCT04099641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab IV infusion
Study NCT04099641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Pembrolizumab IV Infusion
Study NCT06616376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Embolism Stocking
Description: To prevent patients undergoing TKA surgery from being affected by one another, the patients were hospitalized in separate rooms, and the orthopedic clinic team was made aware of the situation. The patients in the control group were told not to remove their socks until the sutures were removed after the operation, whereas the patients in the experimental group were told to remove their socks on the 10th day after the operation, so the patients had no idea which group they were in.
Study NCT06677853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Maleate Gel+Placebo
Description: Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.
Study NCT06677853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Maleate Gel
Description: Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.
Study NCT06677853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.
Study NCT02191566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 (452500ACH)
Description: S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
Study NCT02191566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXALIPLATIN (205803BIJ)
Description: Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
Study NCT04721496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power and Speed
Description: Analysis of the power and speed of execution in 6 conditions of increasing instability Situation 1 is stable and basic execution. Condition 6 is the most unstable.~The participants performed 2 series of 3 repetitions in each of the situations. All the exercises were executed on the same day.
Study NCT02156154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Acetaminophen
Study NCT02156154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen
Study NCT01841541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral of presumptive of TB cases by informal providers
Description: Training of informal providers to effectively refer TB suspects in the community to the primary health care system
Study NCT02904538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02904538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic saline
Study NCT03027908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride Toothpaste 1
Description: Toothpaste containing 1450 ppm F as Sodium Fluoride
Study NCT03027908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Toothpaste 2
Description: Toothpaste containing 1450 ppm F as Sodium Fluoride
Study NCT01816568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILS appendectomy
Description: Single incision laparoscopic appendectomy will be performed
Study NCT01816568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three port laparoscopic appendectomy
Description: Three port laparoscopic appendectomy will be performed
Study NCT04060134 — intervention group
Intervention type: OTHER
Intervention: SimpliDerm HADM
Description: Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
Study NCT04060134 — intervention group
Intervention type: OTHER
Intervention: AlloDerm HADM
Description: Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
Study NCT04060134 — intervention group
Intervention type: OTHER
Intervention: AlloMax HADM
Description: Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
Study NCT04060134 — intervention group
Intervention type: OTHER
Intervention: FlexHD HADM
Description: Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
Study NCT04060134 — intervention group
Intervention type: OTHER
Intervention: DermACELL HADM
Description: Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
Study NCT00480649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/ fluticasone propionate
Description: 2 active arms (parellel group)
Study NCT01758133 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exposure to medical clown activities
Study NCT00249015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
Study NCT00249015 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
Study NCT03883555 — intervention group
Intervention type: DEVICE
Intervention: High flow nasal therapy (HFNT) : Optiflow™
Description: HFNT will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance
Study NCT03883555 — intervention group
Intervention type: DEVICE
Intervention: Non invasive ventilation (niv)
Description: NIV will be delivered through a face mask connected to a dedicated ventilator with pressure support applied in a noninvasive ventilation mode (Monnal T75, Airliquide Medical Systems, Antony, France).~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
Study NCT01435824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human milk-dissolved amoxicillin
Description: An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
Study NCT01435824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Water-dissolved amoxicillin
Description: An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
Study NCT03327350 — intervention group
Intervention type: DEVICE
Intervention: WATCHMAN transplantation
Description: WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic
Study NCT03327350 — intervention group
Intervention type: DRUG
Intervention: Oral anticoagulant drugs
Description: This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
Study NCT03084809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells+ FOLFOX4
Description: Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks. Collected CIK cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days.
Study NCT03084809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
Study NCT01090817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSC) for infusion
Description: MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
Study NCT01961258 — intervention group
Intervention type: OTHER
Intervention: Computerized data base analysis and sampling of patients for outpatient clinic evaluation
Study NCT03813225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral serratus Intercostal plane Block
Description: Will be performed by echo guided one puncture in the fifth costal arch with anterior axilary line, where the tip of the needle will be guided until it reaches a point above the external intercostal muscle, below the anterior serratus above the costal arch where they will be administered 21 ml of anesthesic mass, (20 ml of levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone.)
Study NCT03716635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: 2.5c cold saline is used as a final flush after chemomechanical preparation
Study NCT03716635 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: normal saline
Description: a room temperature saline is used as a final flush after mechanical preparation
Study NCT01143649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Subjects will be stimulated at 1 mA for 40 minutes.
Study NCT01143649 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Subjects will be stimulated at 1 mA for 40 minutes.
Study NCT01143649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: constraint induced movement therapy (CIMT)
Study NCT01845896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Study NCT00603980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo
Study NCT04026620 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Informational Pamphlet
Description: The control group will be provided with two (2) informational pamphlets (and have it read to those who are of lower literacy). Pamphlets contain information about the harmful effects of drinking alcohol during pregnancy and the harmful effects of alcohol on the unborn baby.
Study NCT04026620 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Motivational Enhancement Therapy (MET) Session
Description: The case control trial/efficacy study will provide a one-session MET session in Afrikaans (the predominant language of the region). The face-to-face session will provide information to help people and pregnant women who want to change their drinking behavior, become 'dry' and stay motivated to change their drinking behaviors. Sessions will be approximately one (1) hour and 30 minutes.
Study NCT01137292 — intervention group
Intervention type: DRUG
Intervention: voriconazole (VFEND®)
Description: The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (\<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
Study NCT00038103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
Study NCT00038103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib + Exemestane
Description: Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
Study NCT03254394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study.
Study NCT03254394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% in water will be administered as active comparator.
Study NCT03254394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days.